STK11 and non-small cell lung carcinoma: However, another study reported that NSCLC patients on anti PD-1 immunotherapy who harbored co-mutations with STK11 and KRAS (n = 36) had longer OS in comparison to patients who harbored STK11 mutations alone (13.6 ± 3.4 months, p = 0.049, n = 37).